Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

University of British Columbia

$34,000.00

C. elegans as a tool to discover new anthelmintics.

EF 2016-17

Résumé
As pointed out by the World Health Organization (WHO) ""Helminth infections impose a great burden on poor populations in the developing world."" According to a report by WHO, approximately 2 billion humans have nematode infections worldwide. Nematodes are also serious parasites of livestock and plants and cost billions of dollars a year in crop damage and loss of livestock. Ivermectin is currently the drug of choice to treat nematode infections. Unfortunately, but not unexpectedly, resistance to anthelmintic drugs in general and ivermectin in particular is growing worldwide. These reports of ivermectin resistance are cause for concern and have many organizations calling for the development of new drugs to treat nematode infections. We believe the non-infectious nematode C. elegans can be used as an efficient surrogate for infectious nematodes. The ease of handling of C. elegans in a laboratory environment make it ideal for drug screening and discovery. We have developed a high throughput screening system that will allow us to explore a wide sampling of the chemical landscape for potential nematicides. Chemicals effective on nematodes may be rare, but if we can sample many chemicals easily we have a reasonable chance of identifying new nematicides. This ease and pace of primary screening in tis nematode should lead to identification of new lead chemicals to be developed as nematicides. In a pilot study with a known set of 3,000 FDA approved drugs we identified over 95% of the known nematicides. While the screen is still in progress we already have identified several candidate compounds. None of these compounds have previously been shown to affect nematodes and indeed there is little known about any of the compounds. From the perspective of an anthelmintic we are primarily interested in doing further research on compounds with effects limited to nematodes. Part of our filtering was directed at looking for new chemical backbone's as they may be the most likely to affect biochemical pathways in the nematode that have not yet been exploited. We believe this is a promising approach for developing new anthelmintic drugs. To identify affected pathways for these compounds and possible modes of resistance we will select for drug-resistant animals after mutagenesis and then identify the affected loci. While this has been a time-honored approach used in C. elegans to identify genes involved in drug resistance, determining the molecular identity of affected loci can be a bottleneck. We have developed a multiplex sequencing protocol to identify resistant genes quite easily and it will be applied to resistant strains derived from this project. Longer-term goals will be to work with parasitology labs to see that these drugs get tested on their intended target organisms. If successful we hope to move these compounds into manufacture and testing to help alleviate anthelmintic infections worldwide.
Programme
Discovery Grants Program - Individual
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
RGPIN-2015-04129
Name nom
Moerman, Donald
Department département
Zoology - Zoology
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2015
Award amount
34000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
6404
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Pharmacology
Research subject fr
Pharmacologie
Partie
2
Nb partie
5
Application title
C. elegans as a tool to discover new anthelmintics.
Keyword
NSERC
Application summary
As pointed out by the World Health Organization (WHO) ""Helminth infections impose a great burden on poor populations in the developing world."" According to a report by WHO, approximately 2 billion humans have nematode infections worldwide. Nematodes are also serious parasites of livestock and plants and cost billions of dollars a year in crop damage and loss of livestock. Ivermectin is currently the drug of choice to treat nematode infections. Unfortunately, but not unexpectedly, resistance to anthelmintic drugs in general and ivermectin in particular is growing worldwide. These reports of ivermectin resistance are cause for concern and have many organizations calling for the development of new drugs to treat nematode infections. We believe the non-infectious nematode C. elegans can be used as an efficient surrogate for infectious nematodes. The ease of handling of C. elegans in a laboratory environment make it ideal for drug screening and discovery. We have developed a high throughput screening system that will allow us to explore a wide sampling of the chemical landscape for potential nematicides. Chemicals effective on nematodes may be rare, but if we can sample many chemicals easily we have a reasonable chance of identifying new nematicides. This ease and pace of primary screening in tis nematode should lead to identification of new lead chemicals to be developed as nematicides. In a pilot study with a known set of 3,000 FDA approved drugs we identified over 95% of the known nematicides. While the screen is still in progress we already have identified several candidate compounds. None of these compounds have previously been shown to affect nematodes and indeed there is little known about any of the compounds. From the perspective of an anthelmintic we are primarily interested in doing further research on compounds with effects limited to nematodes. Part of our filtering was directed at looking for new chemical backbone's as they may be the most likely to affect biochemical pathways in the nematode that have not yet been exploited. We believe this is a promising approach for developing new anthelmintic drugs. To identify affected pathways for these compounds and possible modes of resistance we will select for drug-resistant animals after mutagenesis and then identify the affected loci. While this has been a time-honored approach used in C. elegans to identify genes involved in drug resistance, determining the molecular identity of affected loci can be a bottleneck. We have developed a multiplex sequencing protocol to identify resistant genes quite easily and it will be applied to resistant strains derived from this project. Longer-term goals will be to work with parasitology labs to see that these drugs get tested on their intended target organisms. If successful we hope to move these compounds into manufacture and testing to help alleviate anthelmintic infections worldwide.